Educational Tool · TRIUMPH Trial Protocols
Retatrutide TRIUMPH Trial Dose Visualizer (Educational)
This tool visualizes the published TRIUMPH Phase 3 trial dose titration schedule and TRIUMPH-4 outcome data. It is not a dose calculator and does not generate personal recommendations.
⚠ Three Critical Notices — Read Before Proceeding
- Retatrutide is an investigational compound. Not FDA-approved. Not available by prescription.
- This tool visualizes published clinical trial protocols only. It is not a dose recommendation and is not medical advice.
- Do not self-administer investigational compounds. Compounded retatrutide may not match trial-grade formulation. Talk to a licensed clinician.
⚠ Visualizer Disclaimer
This tool visualizes published clinical trial protocols only. It is not a dose recommendation and is not medical advice. Data is from Eli Lilly press releases and ClinicalTrials.gov registrations. Full peer-reviewed data pending publication.
Select Trial Arm to Visualize
Weekly Dose Schedule — Published Trial Protocol
Protocol: Weeks 1–4 at 2 mg, Weeks 5–8 at 4 mg, Weeks 9–12 at 8 mg, Weeks 13–16+ at 12 mg (maintenance through trial end). Source: Published Phase 2 protocol and TRIUMPH program registrations.
TRIUMPH-4 Published Outcomes
Data from December 2025 top-line readout by Eli Lilly. TRIUMPH-4 studied obesity + knee osteoarthritis at 68 weeks. Full peer-reviewed publication pending.
Projected Weight Loss by Dose Tier (TRIUMPH-4)
Approximate weight loss trajectory from TRIUMPH-4 top-line data. Exact week-by-week data pending peer-review publication.
TRIUMPH-4 Tolerability by Dose (at 68 weeks)
Dysesthesia = abnormal skin sensation (tingling/prickling), a new safety signal not seen in Phase 2. Source: BioSpace, December 2025.
28.7%
Weight loss at 68 wks
(12 mg)
75%
Knee OA pain reduction
20.9%
Dysesthesia rate
(12 mg)
18.2%
Discontinuation rate
(12 mg)
How to Read This Visualizer
The dose titration chart shows the published TRIUMPH Phase 3 trial protocol — not a personalized dose schedule. In clinical trials, all participants begin at 2 mg weekly, escalate at 4-week intervals to 4 mg, 8 mg, and 12 mg, then continue at 12 mg (or 9 mg in some trial arms) for the maintenance period through Week 68 or 80.
The tolerability and weight loss charts reflect the December 2025 top-line readout from TRIUMPH-4 specifically (obesity + knee osteoarthritis population). Full week-by-week data, confidence intervals, and subgroup analyses await peer-reviewed publication.
What the Titration Schedule Is Designed to Do
- Weeks 1–4 (2 mg): Low-level receptor engagement to minimize early GI side effects. Most participants tolerate this phase well.
- Weeks 5–8 (4 mg): First major escalation. Appetite suppression becomes more pronounced. Weight loss typically begins to accelerate.
- Weeks 9–12 (8 mg): High-dose phase. GI side effects may peak then stabilize as receptor adaptation occurs. Phase 2 showed ~16% weight loss by this tier.
- Weeks 13+ (12 mg maintenance): Maximum protocol dose. Full metabolic benefits — 28.7% weight loss at 68 weeks in TRIUMPH-4.
Why This Is Not a Dose Calculator
This tool has no inputs for your weight, age, BMI, or health history. It shows only the trial protocols — the dose schedules that Eli Lilly used to evaluate retatrutide in clinical trials. There is no "Calculate" button because there is nothing to calculate: the information here describes what happened in a clinical trial, not what would happen for any individual person.
Retatrutide is not available by prescription. If you are interested in participating in a TRIUMPH trial, discuss eligibility with your physician and search ClinicalTrials.gov.
⚠ Final Disclaimers
- Retatrutide is an investigational compound. Not FDA-approved. Not available by prescription.
- This tool visualizes published clinical trial protocols only. It is not a dose recommendation and is not medical advice.
- Do not self-administer investigational compounds. Compounded retatrutide may not match trial-grade formulation. Talk to a licensed clinician.
Data Sources & Citations
- 1. TRIUMPH-1 — ClinicalTrials.gov: NCT05929066
- 2. TRIUMPH-2 — ClinicalTrials.gov: NCT05929079
- 3. TRIUMPH-3 — ClinicalTrials.gov: NCT05882045
- 4. TRIUMPH-4 top-line data — BioSpace (December 2025): Lilly's retatrutide scores triple trial triumph
- 5. Phase 2 dose protocol — Jastreboff AM et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
More Retatrutide Pages
Frequently Asked Questions
Why is the 12 mg dose the focus of trial reporting?
12 mg was the highest dose studied in Phase 2 and produced the highest weight loss (~24.2%). It is the dose carried into Phase 3 for the maximum-efficacy arm. Lower doses (4 mg, 8 mg) were also studied and produce intermediate efficacy.
Can a patient stay at a lower retatrutide dose long-term?
Yes, that is a clinical decision. Phase 2 data showed meaningful weight loss at 4 mg and 8 mg, lower than 12 mg but still substantially better than placebo. Patients who plateau and prefer lower side-effect burden may choose to remain at a lower dose.
How long does titration take to reach 12 mg?
The standard titration is 2 mg → 4 mg → 6 mg → 8 mg → 10 mg → 12 mg with 4 weeks at each step — approximately 24 weeks (about 6 months) from initiation to maximum dose.
What happens if titration is too fast?
Faster titration increases the rate of moderate-to-severe gastrointestinal side effects substantially without faster weight loss outcomes. The 4-week interval reflects the body's adaptation timescale and is built into the trial protocol for safety reasons.
Is the trial dose the dose that will be marketed?
Probably similar but final labeled doses depend on FDA review. Tirzepatide, for instance, was studied at 5–15 mg in Phase 3 and approved with all of those doses available, allowing physicians to titrate to tolerability. Retatrutide is likely to follow a similar pattern.